Last week, the DEA moved Epidiolex, an epilepsy drug derived from cannabis, into Schedule V, the least restrictive category. The move is a good news for pharmaceutical companies that want to develop their own cannabis-based drugs, but it won’t mean much for other cannabis “wellness” products.

Last week, the DEA moved Epidiolex, an epilepsy drug derived from cannabis, into Schedule V, the least restrictive category. The move is a good news for pharmaceutical companies that want to develop their own cannabis-based drugs, but it won’t mean much for other cannabis “wellness” products.: https://ift.tt/2zOXjus Read more... https://ift.tt/2ybIU9s